Alex Wyatt, Associate Professor and President’s Excellence Chair in Precision Oncology at The University of British Columbia, shared on LinkedIn:
“Here’s our analysis of serial ctDNA, CTCs, and imaging features in mCRPC treated with 177Lu-PSMA-617 and pembrolizumab, published in The Journal of Nuclear Medicine – JNM.
Brainchild of Shahneen Sandhu and spearheaded by postdoc Sofie Tolmeijer, along with a host of engaged collaborators.
Hope it makes for an interesting read! One aspect that was particularly new to us was intersecting bulk ctDNA genome data with single CTC profiles.”
Title: Tumor-Intrinsic Blood and Imaging Correlatives in Advanced Prostate Cancer Treated with Combination Radiopharmaceutical Therapy and Immunotherapy
Authors: Edmond M. Kwan, Andrei Gafita, Anis A. Hamid, Shivakumar Keerthikumar, Narjess Ayati, Mathias Bressel, Anthony M. Joshua, Louise Emmett, Megan Crumbaker, Sarah W.S. Ng, Gráinne Donnellan, Angelyn Anton, Lavinia Spain, Lisa G. Horvath, Joanna Chan, James P. Buteau, Arielle van Mourik, Nattakorn Dhiantravan, Andrisha-Jade Inderjeeth, Martin Sjöström, Aishwarya Subramanian, Santosh Gupta, Narelle Williams, Anupama Pasam, David Olmos, Nicole M. Haynes, Paul J. Neeson, David Quigley, David L. Goode, Rodney J. Hicks, Michael S. Hofman, Alexander W. Wyatt
You can also read:
MOB-RT Supports Moderate Hypofractionated Pelvic Radiotherapy in High-Risk Prostate Cancer
